15-February-2017 — CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). More.
10-February-2017 — An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes. More.
Other recent news:
19-January-2017 — CSL Limited today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016. More.
09-January-2017 — CSL today announced that the European Commission has granted marketing authorisation for CSL Behring's AFSTYLA® for children and adults with haemophilia A. More.
05-January-2017 — Momenta and CSL have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017. More.